The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | PRIMAVERA trial update: AZD3470, a second-generation PRMT5 inhibitor, in R/R Hodgkin lymphoma
Enrico Derenzini, MD, PhD, European Institute of Oncology, Milan, Italy, Milan, Italy, provides an update on the PRIMAVERA study (NCT06137144), a Phase I first-in-human trial evaluating the safety and efficacy of AZD3470, a second-generation PRMT5 inhibitor, in relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). Dr Derenzini shares the rationale for investigating this agent in cHL and outlines the safety and efficacy data that have been reported thus far. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
